MF-766 NEW
| Price | $74 | $178 | $289 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: MF-766 | CAS No.: 1050656-06-8 |
| Purity: 98.06% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | MF-766 |
| Description | MF-766 is a highly potent, selective, and orally active EP4 antagonist with a Ki of 0.23 nM, acting as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It is useful for cancer and inflammation diseases research [1][2]. |
| In vitro | MF-766, at concentrations ranging from 0.01 to 10 μM and pretreated for 1 hour before being stimulated with 50 ng/mL IL-2—both with and without 0.33 μM PGE2 for 18 hours—effectively reverses the suppression of IFN-γ secretion in human NK cells caused by PGE2. Importantly, the viability of NK cells remains unaffected by MF-766[2]. |
| In vivo | MF-766 (oral gavage; 30 mg/kg; once daily; 21 days) exhibits TGI% of 49% in CT26 tumor model. But it does not exhibits significant difference in EMT6 and 4T1 tumor model[2]. MF-766 (oral gavage; 30 mg/kg combination with anti-PD-1 mDX400; once daily; 21 days; q4dx8) shows potent anti-tumor activities in different preclinical models. The % of TGI are 89%, 66% and 40%, respectively in CT26 tumor, EMT6 and 4T1 tumor model[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (125.4 mM), Sonication is recommended. |
| Keywords | EP4 | arthritis | inflammation disease | AIA | inhibit | MF-766 | anti-tumor | MF766 | MF 766 | Prostaglandin Receptor | Inhibitor | cancer |
| Inhibitors Related | Angoroside C | Pranoprofen | Tranilast | Benorilate | Rutin | Ozagrel | Ethamsylate | Rebamipide | Evodiamine | Tebufelone | Timapiprant | p-Hydroxycinnamic acid |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2800.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $36.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-07 | |
| $0.00/10mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-29 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY